Recent LLY news includes positive Phase 3 data for Jaypirca (pirtobrutinib) versus Imbruvica for CLL/SLL, showing superior tolerability metrics as of December 7, 2025. Furthermore, Carolyn R. Bertozzi returned to the board of directors effective December 8, 2025, bringing expertise in targeted medicines.